| International Session（Symposium）4(JSGS・JSGE・JSH・JSGCS) |
| Sat. November 2nd 9:00 - 12:00 Room 9: Portopia Hotel Main Building Kairaku 3 |
| Surveillance and Treatment Strategies for Hepatocellular Carcinoma in Asia | |||
| Jian Zhou | |||
| Zhongshan Hospital Fudan University | |||
|
|||
|
|||
| Hepatocellular carcinoma (HCC) represents a significant health challenge globally, particularly in Asia. With diverse etiologies including chronic viral hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), HCC poses substantial morbidity and mortality risks across the region. Early detection and prompt intervention remain paramount for improving patient outcomes. Surveillance efforts are important in detecting HCC at its early stages when curative treatment options are feasible. Various surveillance modalities, such as alpha-fetoprotein (AFP) testing, ultrasound imaging, and other radiological techniques, are routinely employed to monitor high-risk populations. Recent studies have underscored the importance of integrating these surveillance methods into comprehensive screening programs, allowing for timely diagnosis and intervention. Recent years, the landscape of HCC treatment has witnessed remarkable advancements. Surgical interventions, including liver resection, transplantation, remain cornerstone approaches for eligible candidates, providing curative potential in select cases. However, the expanding armamentarium of non-surgical options has significantly broadened therapeutic possibilities, particularly for patients with unresectable disease or those ineligible for surgery. Among these novel treatments, locoregional therapies such as radiofrequency ablation (RFA) and trans arterial chemoembolization (TACE) have demonstrated efficacy in locally advanced HCC, offering palliative benefits and potentially prolonging survival. Moreover, molecular targeted therapies, notably tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have emerged as promising systemic treatment options. The advent of ICIs, in particular, has revolutionized the management of advanced HCC, with several agents demonstrating favorable outcomes in clinical trials. China, a leading contributor to HCC burden, are at the forefront of pioneering research and innovation in HCC treatment. Contributions include the development of indigenous TKIs and the exploration of combination therapies incorporating traditional Chinese medicine. Furthermore, China's robust healthcare infrastructure and large patient cohorts have facilitated the conduct of pivotal clinical trials, accelerating the translation of research findings into clinical practice. Despite these advancements, several challenges persist in the optimal management of HCC in Asia, including access to healthcare resources, disparities in treatment availability and the need for personalized therapeutic approaches. Collaborative efforts between clinicians, researchers and policymakers are essential to address these challenges and optimize patient outcomes. In conclusion, the surveillance and treatment landscape for HCC in Asia has evolved significantly in recent years. Continued research endeavors and collaborative initiatives are vital to further enhance the effectiveness and accessibility of HCC management strategies across the region, ultimately reducing the burden. |
|||
| Page Top | |||